ENLV ENLV
Company Profile ↓Company Overview
ENLV (ENLV) is a publicly traded company listed on with a market capitalization of $517.49M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 63.8%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.03.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -90.18% |
| 6 Months: | -86.67% |
| 3 Months: | -82.28% |
| 1 Month: | -70.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)14.51 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 63.8%.
CONS
- Trading 92.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 15 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 4.88M | 3.50M | 3.08M | 2.56M | 5.86M |
| Operating Income | -4.88M | -3.50M | -3.08M | -2.56M | -5.86M |
| EBITDA | -4.84M | -3.41M | -2.99M | -2.48M | -5.79M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -5.18M | -3.45M | -1.87M | -2.21M | 1.63B |
| Tax Provision | - | - | - | - | - |
| Net Income | -5.18M | -3.45M | -1.87M | -2.21M | 1.24B |
| Diluted EPS | - | -0.15 | -0.08 | -0.09 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 25.80M | 25.15M | 14.93M | 15.00M |
| Operating Income | - | -25.80M | -25.15M | -14.93M | -15.00M |
| EBITDA | - | -25.02M | -24.32M | -14.39M | -14.67M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -31.06M | -29.07M | -15.01M | 1.62B |
| Tax Provision | - | - | 0 | 0 | 382.65M |
| Net Income | - | -31.06M | -29.07M | -15.01M | 1.24B |
| Diluted EPS | -0.81 | -1.69 | -1.56 | -0.73 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 67.64M | 36.83M | 27.69M | 2.33B |
| Current Assets | - | 52.33M | 33.76M | 25.99M | 1.74B |
| Cash & Equivalents | - | 49.95M | 813.00K | 3.30M | 1.89M |
| Inventory | - | - | - | - | - |
| Receivables | 2.20M | - | - | - | - |
| Total Liabilities | - | 10.80M | 6.75M | 4.10M | 392.05M |
| Current Liabilities | - | 6.61M | 6.06M | 3.80M | 9.02M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.85M | 1.03M | 534.00K | 641.00K |
| Total Equity | - | 56.84M | 30.08M | 23.59M | 1.93B |
| Shares Outstanding | - | 18.42M | 18.60M | 23.65M | 237.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.95M | -23.52M | -13.01M | -10.42M |
| Investing Cash Flow | - | 62.52M | -25.97M | 9.06M | -1.32M |
| Financing Cash Flow | - | 150.00K | 360.00K | 6.45M | 10.38M |
| Capital Expenditure | - | -8.12M | -236.00K | -103.00K | -68.00K |
| Free Cash Flow | - | -32.08M | -23.76M | -13.11M | -10.48M |
| Net Change in Cash | - | 38.72M | -49.13M | 2.50M | -1.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -54.6% | -96.6% | -63.6% | 63.9% |
| ROCE % | - | -42.3% | -81.7% | -62.5% | -0.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENLV
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher…
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.…
Enlivex advances Allocetra while expanding into prediction markets
Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction ma…
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts a…
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Enlivex Ltd. is one of the oversold stocksto invest in now. TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 wh…
ENLV — Frequently Asked Questions
What is the current share price of ENLV?
As of 2026-08-05 17:25 PDT, ENLV trades at $2.18 on NASDAQ/NYSE. Its 52-week range is $1.95 to $27.30.
What is the market capitalisation of ENLV?
ENLV has a market capitalisation of $517.49M on NASDAQ/NYSE.
What is the P/E ratio of ENLV?
ENLV trades at a trailing price-to-earnings (P/E) ratio of -2.99. Its price-to-book (P/B) ratio is 0.27.
What is the return on equity (ROE) of ENLV?
ENLV has a return on equity (ROE) of 63.85%. Its return on capital employed (ROCE) is -0.65%.
Is ENLV a good stock to buy?
This page provides a data-driven analysis of ENLV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.